Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats

Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase and have a major place in the treatment of atherosclerotic disease. Recent studies have shown anti-inflammatory properties of statins. The purpose of this study was to evaluate the anti-inflammatory effect of simvastatin on bleomycin (BLM)-induced pulmonary fibrosis in rats. A total of 31 female Sprague-Dawley rats were divided into four groups: (1) intratracheal (IT) phosphate-buffered saline (PBS) + intraperitoneal (IP) PBS (n=7); (2) IT BLM + IP PBS (n=8); (3) IT BLM + low dose (LD) simvastatin (1 mg/kg daily, n=8); (4) IT BLM + high dose (HD) simvastatin (5 mg/kg daily, n=8). Simvastatin was administered IP for 15 days, beginning 1 day prior to IT BLM. The effect of simvastatin on pulmonary fibrosis was studied by measurements of IL-13, PDGF, IFN-&#947;, TGF-p1 levels in bronchoalveolar lavage (BAL) fluid and lung tissue hydroxyproline (HPL) content and by histopathological examination (Ashcroft score). BLM caused significant change in BAL fluid cytokine levels and increased both HPL content and histopathological score (p<0.001 for all). While LD simvastatin had no effect on cytokine levels, HD significantly reduced IL-13 (15.12 ±7.08 pg/ml vs. 4.43±2.34 pg/mL; p<0.05) and TGF-&#946;1 levels (269.25 ±65.42 pg/mL vs. 131.75±32.65 pg/mL; p<0.05). Neither HD nor LD simvastatin attenuated HPL content or Ashcroft score. In conclusion, this study showed that LD simvastatin had no effect on a BLM-induced pulmonary fibrosis model, while the high dose caused partial improvement in profibrotic cytokine levels.

Saved in:
Bibliographic Details
Main Authors: Tulek,Baykal, Kiyan,Esen, Kiyici,Aysel, Toy,Hatice, Bariskaner,Hulagu, Suerdem,Mecit
Format: Digital revista
Language:English
Published: Sociedad de Biología de Chile 2012
Online Access:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602012000400003
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0716-97602012000400003
record_format ojs
spelling oai:scielo:S0716-976020120004000032013-03-15Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female ratsTulek,BaykalKiyan,EsenKiyici,AyselToy,HaticeBariskaner,HulaguSuerdem,MecitStatins reduce cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase and have a major place in the treatment of atherosclerotic disease. Recent studies have shown anti-inflammatory properties of statins. The purpose of this study was to evaluate the anti-inflammatory effect of simvastatin on bleomycin (BLM)-induced pulmonary fibrosis in rats. A total of 31 female Sprague-Dawley rats were divided into four groups: (1) intratracheal (IT) phosphate-buffered saline (PBS) + intraperitoneal (IP) PBS (n=7); (2) IT BLM + IP PBS (n=8); (3) IT BLM + low dose (LD) simvastatin (1 mg/kg daily, n=8); (4) IT BLM + high dose (HD) simvastatin (5 mg/kg daily, n=8). Simvastatin was administered IP for 15 days, beginning 1 day prior to IT BLM. The effect of simvastatin on pulmonary fibrosis was studied by measurements of IL-13, PDGF, IFN-&#947;, TGF-p1 levels in bronchoalveolar lavage (BAL) fluid and lung tissue hydroxyproline (HPL) content and by histopathological examination (Ashcroft score). BLM caused significant change in BAL fluid cytokine levels and increased both HPL content and histopathological score (p<0.001 for all). While LD simvastatin had no effect on cytokine levels, HD significantly reduced IL-13 (15.12 ±7.08 pg/ml vs. 4.43±2.34 pg/mL; p<0.05) and TGF-&#946;1 levels (269.25 ±65.42 pg/mL vs. 131.75±32.65 pg/mL; p<0.05). Neither HD nor LD simvastatin attenuated HPL content or Ashcroft score. In conclusion, this study showed that LD simvastatin had no effect on a BLM-induced pulmonary fibrosis model, while the high dose caused partial improvement in profibrotic cytokine levels.info:eu-repo/semantics/openAccessSociedad de Biología de ChileBiological Research v.45 n.4 20122012-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602012000400003en10.4067/S0716-97602012000400003
institution SCIELO
collection OJS
country Chile
countrycode CL
component Revista
access En linea
databasecode rev-scielo-cl
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Tulek,Baykal
Kiyan,Esen
Kiyici,Aysel
Toy,Hatice
Bariskaner,Hulagu
Suerdem,Mecit
spellingShingle Tulek,Baykal
Kiyan,Esen
Kiyici,Aysel
Toy,Hatice
Bariskaner,Hulagu
Suerdem,Mecit
Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats
author_facet Tulek,Baykal
Kiyan,Esen
Kiyici,Aysel
Toy,Hatice
Bariskaner,Hulagu
Suerdem,Mecit
author_sort Tulek,Baykal
title Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats
title_short Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats
title_full Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats
title_fullStr Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats
title_full_unstemmed Effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats
title_sort effects of simvastatin on bleomycin-induced pulmonary fibrosis in female rats
description Statins reduce cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase and have a major place in the treatment of atherosclerotic disease. Recent studies have shown anti-inflammatory properties of statins. The purpose of this study was to evaluate the anti-inflammatory effect of simvastatin on bleomycin (BLM)-induced pulmonary fibrosis in rats. A total of 31 female Sprague-Dawley rats were divided into four groups: (1) intratracheal (IT) phosphate-buffered saline (PBS) + intraperitoneal (IP) PBS (n=7); (2) IT BLM + IP PBS (n=8); (3) IT BLM + low dose (LD) simvastatin (1 mg/kg daily, n=8); (4) IT BLM + high dose (HD) simvastatin (5 mg/kg daily, n=8). Simvastatin was administered IP for 15 days, beginning 1 day prior to IT BLM. The effect of simvastatin on pulmonary fibrosis was studied by measurements of IL-13, PDGF, IFN-&#947;, TGF-p1 levels in bronchoalveolar lavage (BAL) fluid and lung tissue hydroxyproline (HPL) content and by histopathological examination (Ashcroft score). BLM caused significant change in BAL fluid cytokine levels and increased both HPL content and histopathological score (p<0.001 for all). While LD simvastatin had no effect on cytokine levels, HD significantly reduced IL-13 (15.12 ±7.08 pg/ml vs. 4.43±2.34 pg/mL; p<0.05) and TGF-&#946;1 levels (269.25 ±65.42 pg/mL vs. 131.75±32.65 pg/mL; p<0.05). Neither HD nor LD simvastatin attenuated HPL content or Ashcroft score. In conclusion, this study showed that LD simvastatin had no effect on a BLM-induced pulmonary fibrosis model, while the high dose caused partial improvement in profibrotic cytokine levels.
publisher Sociedad de Biología de Chile
publishDate 2012
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-97602012000400003
work_keys_str_mv AT tulekbaykal effectsofsimvastatinonbleomycininducedpulmonaryfibrosisinfemalerats
AT kiyanesen effectsofsimvastatinonbleomycininducedpulmonaryfibrosisinfemalerats
AT kiyiciaysel effectsofsimvastatinonbleomycininducedpulmonaryfibrosisinfemalerats
AT toyhatice effectsofsimvastatinonbleomycininducedpulmonaryfibrosisinfemalerats
AT bariskanerhulagu effectsofsimvastatinonbleomycininducedpulmonaryfibrosisinfemalerats
AT suerdemmecit effectsofsimvastatinonbleomycininducedpulmonaryfibrosisinfemalerats
_version_ 1755990913732050944